|
Eight International Congress on Drug Therapy in HIV InfectionGlasgow, UK - 12-16 November 2006 |
Cite as: Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P40
| Plenary Sessions |
|
| KL1 - Keynote Lectures (Past, Present and Future) |
|
| KL1 | [KL1] WHERE DID IT ALL BEGIN? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL1 Paul M Sharp The numbers of examples of SIVcpz and SIVsmm characterized have been extremely limited. To learn more about these viruses, and the origins of HIV-1 and HIV-2, non-invasive techniques have been developed and used to greatly increase the number of strains sampled from wild populations of sooty mangabeys and chimpanzees. We have found the closest SIVsmm relatives of the two epidemic forms of HIV-2 in Cote dIvoire. The closest SIVcpz relatives of HIV-1 infect one particular subspecies of chimpanzees, Pan troglodytes troglodytes, in West Central Africa. We have now found widespread endemic infection in these apes, with SIVcpz prevalence rates over 20% in some communities. SIVcpz strains exhibit a local phylogeographic clustering, allowing us to trace the origins of pandemic (group M) and non-pandemic (group N) HIV-1 to distinct, geographically isolated chimpanzee communities in southern Cameroon. Thus, 25 years into the AIDS epidemic, the origins of this newly emerged disease have been elucidated. |
| KL2 | [KL2] WHERE ARE WE WITH ART IN 2006? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL2 Roy M Gulick Other areas of active investigation offer promise in relation to newer diagnostic tests, newer treatment strategies and a number of investigational antiretroviral agents, including HIV integrase inhibitors and HIV maturation/gag processing inhibitors. Acknowledging our substantial progress with ART to date, additional gains may be anticipated. |
| KL3 | [KL3] WHERE ARE WE GOING WITH HIV PREVENTION, TREATMENT AND CARE AT A GLOBAL LEVEL? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL3 Kevin M De Cock As increased numbers of people access treatment, resource requirements for HIV/AIDS will also increase, highlighting the need for effective prevention and innovative financing methods. How HIV/AIDS will fare in global prioritization in the coming decade will depend on epidemiologic trends as well as programmatic performance, in a complex world with other emerging threats. |
| PL1 - Treatment Strategies |
|
| PL1.1 | [PL1.1] CLINICAL USE OF VARIOUS HIV TREATMENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1 Manuel Battegay Potent antiretroviral therapy (ART) has dramatically and increasingly reduced long-term morbidity and mortality since the mid-1990s. With the advent of many new drugs in recent years, multiple options have become available for initiating ART. Regimen design considerations include efficacy, durability, tolerability and long-term adverse effects, convenience, and drug-interactions, as well as the potential for salvaging the initial regimen (IAS USA and DHHS guidelines). |
| PL1.2 | [PL1.2] Antiretroviral therapy for prevention of transmission of HIV-1 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.2 Myron S Cohen Substantial limitations for ART for prevention include the treatment of the right people at the right time(s), viral resistance, and the potential inspiration of risky sexual behavior. |
| PL1.3 | [PL1.3] New treatment paradigms for experienced patients Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.3 David Cooper Abstract not available. |
| PL1.4 | [PL1.4] Antiretroviral treatment strategies for the next decade Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL1.4 Mark Harrington Abstract not available. |
| PL2 - Open Papers |
|
| PL2.1 | [PL2.1] HIV-associated renal disease Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.1 John Connolly HIV is associated with a wide spectrum of renal disease. Viral infection gives rise to a collapsing glomerulopathy (HIVAN) in susceptible patients which may be responsive to antiretroviral therapy (ART). HIV is also associated with a variety of immune complex glomerular diseases in which the role of ART is less clear. |
| PL2.2 | [PL2.2] Susceptibility of a protease inhibitor (PI) treatment-experienced UK clinical cohort to TMC-114 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.2 C Loveday, E MacRae, on behalf of the ICVC Clinical Collaborative Research Group In this PI treatment-experienced clinical cohort, the majority had very low frequency of TMC-114 related mutations. Only 10 patients had ≥10 PR mutations with 2 patients including 4 HI mutations. Based on these data TMC-114 should be of benefit to PI treatment-experienced patients in a UK clinical cohort. |
| PL2.3 | [PL2.3] INDUCTION-MAINTENANCE ANTIRETROVIRAL THERAPY WITH TRIZIVIR PLUS EITHER EFAVIRENZ OR LOPINAVIR/R: RESULTS OF A MULTICENTRE RANDOMIZED CLINICAL TRIAL AT 72 WEEKS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.3 J Mallolas, M Penaranda, P Domingo, H Knobel, E Pedrol, F Gutierrez, P Barrufet, J Peraire, D Dalmau, E Ribera, A Ocampo, MA Muniain, C Alonso, V Estrada, JR Blanco, J Cucurull, J Pich, E De Lazzari, A Leon ARV-naïve patients undergoing induction with TZV + EFV or LPV/r followed by maintenance with TZV achieved adequate immunological and virological response at W72. The study shows a trend to an increased VF in EFV arm. |
| PL2.4 | [PL2.4] WIDE DISPARITY IN SWITCH TO SECOND-LINE THERAPY IN HIV-INFECTED CHILDREN IN CHIPS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.2 K J Lee, H Lyall, A S Walker, M Sharland, A Judd, D M Gibb CD4 and VL, and timing of switch in relation to different VL thresholds vary widely in children across all ages. There is urgent need for evidence on which to base switching. |
| PL2.5 | [PL2.5] Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naïve HIV-1 infected patients: GEMINI Study Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL2.5 J. Slim, A. Avihingsanon, K. Ruxrungtham, M. Schutz, S. Walmsley At Wk 24, SQV/r appears comparable to LPV/r in terms of efficacy and tolerability. Non-inferiority of the regimen and lipid differences will be evaluated in the final 48-wk analysis. |
| PL3 - New Challenges in Providing ART [IAS Session] |
|
| PL3.1 | [PL3.1] NEW CHALLENGES OF PROVIDING HAART: LESSONS FROM THE FRONTLINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.1 Elly T Katabira Providing ART in resource-limited settings requires a dedicated and robust team of health professionals, administrators and community leaders. Team members should be flexible and highly innovative. They should be able to work with their patients more closely and support each other at all times in order to realise the rewards of ART that have been seen in the developed world. |
| PL3.2 | [PL3.2] HOW EFFECTIVE IS THE 'WHO MONITORING SYSTEM' FOR PATIENTS ON ANTIRETROVIRAL TREATMENT? LESSONS LEARNT DURING THE ROLL-OUT OF ANTIRETROVIRALS IN THE WESTERN CAPE PROVINCE, SOUTH AFRICA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.2 Peter Bock, Andrew Boulle, Meg Osler Patient retention and viral load suppression rates are highly comparable with data from other studies; indicating the feasibility of an antiretroviral program in the public health sector in South Africa. The monitoring system had proved effective; however experience in the field has shown that improvements to its design and implementation need to be made. |
| PL3.3 | [PL3.3] GLOBAL RESISTANCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.3 Luis Soto-Ramirez The availability of HAART that suppresses replication of HIV-1, has dramatically improved the prognosis of HIV-infected patients. Unfortunately, HAART does not durably suppress HIV replication in 20 to more than 50% of treatment-naïve patients and in up to 50-70% of treatment-experienced patients. |
| PL3.4 | [PL3.4] HIV-1 SUBTYPE C VIRUSES RAPIDLY DEVELOP K65R RESISTANCE AGAINST ddI AND TENOFOVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.4 Mark A Wainberg, Florence Doualla-Bell, Tendani Gaolathe, Madisa Mine, Max Essex, Bluma Brenner K65R may emerge at higher frequency in individuals infected with subtype C viruses who experience treatment with certain NRTIs, establishing the need to monitor for the presence of this mutation and its possible transmission. |
| PL3.5 | [PL3.5] THE NEED FOR PHARMACOVIGILANCE IN THE RESOURCE-LIMITED SETTING: AN INDUSTRY PERSPECTIVE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.5 Didier Lapierre Traditionally clinical research has been mainly performed in the “Western World” where medical infrastructures are available. Drug development in resource poor setting was limited by lack of capacities but also by ethical and access challenges. Globalisation of the R&D is a new reality firstly to fulfil the unmet medical needs of 80% of the world population and of the HIV patients in particular but it is also attractive from a drug development point of view. |
| PL3.6 | [PL3.6] NEW CHALLENGES IN ART ROLL-OUT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL3.6 Charles Gilks The main donors are all committed to (as close as possible) universal access to ART by 2010. To come close to this noble goal, major challenges and constraints will have to be identified and overcome:... |
| PL4 - Clinical Pharmacology and Resistance |
|
| PL4.1 | [PL4.1] ANTIRETROVIRAL THERAPY AND PHAMACOGENOMICS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.1 David Haas Pharmacogenomics also holds promises to suggest novel targets for drug development. This is highlighted by the discovery that a non-functional variant of the HIV receptor gene CCR5 protected against HIV infection, prompting development of therapeutic CCR5 antagonists. |
| PL4.2 | [PL4.2] THE PLACE FOR THERAPEUTIC DRUG MONITORING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.2 Marta Boffito The potential for undesirable drug interactions is the main reason for interest in therapeutic drug monitoring (TDM): important drug interactions may occur among antiretrovirals (ARVs) belonging to the same or to different classes or between ARVs and drugs received by HIV patients for the treatment of co-existing medical conditions, the treatment and prevention of opportunistic infections, for supportive care or for the management of adverse events caused by ARVs. |
| PL4.3 | [PL4.3] THE PLACE OF DRUG RESISTANCE TESTING IN THE CLINICAL MANAGEMENT OF HIV Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.3 Annemarie Wensing In most European countries, drug resistance testing has become part of routine clinical management of HIV infection, particularly at the time of antiretroviral therapy failure. Genotypic testing is performed most frequently because of its relatively low cost, technical convenience and virological benefit shown in clinical trials. |
| PL4.4 | [PL4.4] DRUG RESISTANCE TESTING AND THERAPEUTIC DRUG MONITORING IN HIV-1 INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL4.4 Daniel R Kuritzkes Drug resistance testing has become an essential tool for the management of antiretroviral therapy. Increasing rates of transmission of drug-resistant virus in the United States and cost-effectives analyses support the use of drug resistance testing as an essential part of initial patient evaluation, prior to starting antiretroviral therapy. |
| PL5 - Oral Papers |
|
| PL5.1 | [PL5.1] USE OF TMC114 IN COMBINATION WITH OTHER DRUGS: GUIDANCE FROM PHARMACOKINETIC STUDIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.1 D Back, V Sekar, E Lefebvre, M De Pauw, E De Paepe, T Vangeneugden, R Hoetelmans TMC114/r can be combined with many drugs with no TMC114/r dose adjustments. Some co-administered drugs may require dose adjustments (SIL, AVS, KTZ and IDV). Combining TMC114/r with LPV/r or SQV/r is not recommended. Additional contraception should be used when OC are combined with TMC114/r. Current evidence shows that DIs between TMC114/r and drugs commonly used in HIV-infected patients are well characterised and manageable. |
| PL5.2 | [PL5.2] TMC125 IN COMBINATION WITH OTHER MEDICATIONS: SUMMARY OF DRUG-DRUG INTERACTION STUDIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.2 Thomas N Kakuda, Monika Schöller-Gyüre, Brian Woodfall, Goedele De Smedt, Monika Peeters, Kati Vandermeulen, Richard M Hoetelmans TMC125 can be combined with most of the drugs studied without dosage adjustment. Dose adjustments may be required for FPV and SIL. It is not recommended to combine TMC125 with TPV/rtv. Drug interactions between TMC125 and medications commonly used in HIV therapy are well characterized and manageable. |
| PL5.3 | [PL5.3] INVOLVEMENT OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE POLYMORPHISMS (UGT) IN ATAZANAVIR TOXICITY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.3 Ulrike Moebius, T O Lankisch, M Wehmeier, G M Behrens, M P Manns, R E Schmidt, C P Strassburg GD-associated jaundice in ATV-treated patients is a phenotype associated with a novel UGT1A gene haplotype encompassing four genetic variants with altered glucuronidation activity of the affected genes. In normal individuals these variants do not occur in linkage dysequilibrium. The detection of variants at the UGT1A gene locus is a potentially powerful pharmacogenetic tool contributing to prediction and identification of drug-associated toxicity and disease susceptibility. |
| PL5.4 | [PL5.4] THE ASSESSMENT OF MULTI-LOCUS GENE EFFECTS UPON LOPINAVIR PHARMACOKINETICS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.4 A Owen, T Mahungu, C Cook, M Youle, M Johnson, D Back, S Khoo These data are preliminary but suggest that cumulative scoring algorithms can be developed to assess multi-locus genetic effects influencing LPV pharmacokinetics. |
| PL5.5 | [PL5.5] DECLINING INCIDENCE OF MULTIDRUG-RESISTANT HIV-1 OVER TIME (2001-2006): WHICH NEW DRUGS DO WE REALLY NEED? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.5 J Vercauteren, K Theys, M Debruyne, A P Carvalho, A M Vandamme, R Camacho The incidence of MDR is decreasing over time in Portugal, reflecting the increasing efficiency of HAART. We anticipate that, in a near future, activity against resistant viruses will not be the primary target for the design of new drugs. Better tolerability, ease of use or less toxicity may instead be favored. |
| PL5.6 | [PL5.6] IMPACT OF NNRTI AND NRTI RESISTANCE ON THE RESPONSE TO THE REGIMEN OF TMC125 PLUS TWO NRTIS IN STUDY TMC125-C227 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL5.6 B Woodfall, J Vingerhoets, M Peeters, I Peeters, G De Smedt, GD Miralles, M.P. de Béthune In this study, in PI-naïve patients having failed a first-line NNRTI regimen, the level of NNRTI and NRTI resistance was higher than expected. Since patients were PI naïve, these higher levels of baseline resistance probably account for the difference in outcome between the TMC125 and PI arms. Given the demonstrated long-term virological benefit of TMC125 in patients with NNRTI and PI resistance, evaluation of TMC125 in NNRTI and PI experienced patients continues in ongoing Phase III trials. |
| PL6 - HIV-related Infections, Co-infections and Malignancies I |
|
| PL6.1 | [PL6.1] NEW TREATMENTS IN HEPATITIS C AND B CO-INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.1 Jürgen Rockstroh HIV has been shown to accelerate the progression of hepatitis C and B, and to result in higher liver disease related mortality and morbidity, thereby clearly underlining the importance of treating HIV patients for underlying hepatitis. A number of important clinical studies were able to show that the introduction of pegylated interferon plus ribavirin combination therapy has significantly improved treatment outcome and that sustained virological response rates (SVR) over 40% in HIV/HCV co-infected individuals seem achievable. |
| PL6.2 | [PL6.2] INFLUENCE OF THE STAGE OF LIVER FIBROSIS ON PLASMA LEVELS OF ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.2 C Pablo Barreiro, Sonia Rodriguez-Novoa, Pablo Labarga, Andres Ruiz-Sancho, Carol Castellares, Marina Nuñez, Inmaculada Jimenez-Nacher, Luz Martin-Carbonero, Juan Gonzalez-Lahoz, Vincent Soriano Liver clearance of NNRTI, particularly of EFV, seems to be impaired in cirrhotics, what translates into higher plasma drug levels. These patients might benefit from therapeutic drug monitoring to avoid drug overexposure. No similar effect was seen for PI. LF assessment by non-invasive tools may identify HCV/HIV patients that warrant antiretroviral dose adjustments in order to minimize toxicities. |
| PL6.3 | [PL6.3] ORGAN TRANSPLANTATION IN HIV-INFECTED PATIENTS – MANAGEMENT AND OUTCOME EXPERIENCES FROM EUROPE AND NORTH AMERICA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.3 José M Miró With the recent advent of highly active antiretroviral therapy (HAART), those patients infected with HIV are now living longer and dying from illnesses other than acquired immunodeficiency syndrome (AIDS). Liver disease due to chronic hepatitis B and C is now a leading cause of mortality among HIV-infected patients in the developed world. |
| PL6.4 | [PL6.4] THE MANAGEMENT OF TB IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL6.4 Stephen D Lawn The management of tuberculosis (TB) in HIV-infected patients remains a clinical challenge, especially for those working in resource-limited settings with high TB incidence. In this talk, the burden of TB among patients accessing antiretroviral treatment (ART) in both high-income and resource-limited settings will be described, and the long-term impact of treatment on risk of TB will be reviewed. |
| PL7 - HIV-related Infections, Co-infections and Malignancies II |
|
| PL7.1 | [PL7.1] HUMAN PAPILLOMAVIRUS INFECTION – WHERE ARE WE? HPV VACCINATION LAUNCHES PROMOTION OF SEXUAL HEALTH IN POPULATION-BASED COHORTS OF THE YOUNG Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.1 Matti Lehtinen The most effective way of controlling common sexually transmitted diseases (STD) is inclusion of efficacious preventive measures into national vaccination/screening programmes directed to the young in a coordinated and evaluable, i.e., randomized manner. Our trial is a proof of principle on how population-based cohorts and biobanks can provide new knowledge on implementation and evaluation of these programmes. Improved understanding from molecular epidemiology of the common STDs to cost-effectiveness of the interventions against the common STDs is gained, and propects for eradication of both the infectious causes and the diseases are evaluated. |
| PL7.2 | [PL7.2] THE RISK OF NON-AIDS DEFINING MALIGNANCIES IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.2 Alexandra M Levine The use of highly active anti-retroviral therapy (HAART) has resulted in a dramatic decrease in AIDS-defining Kaposi’s sarcoma and non-Hodgkin’s lymphoma, while its impact has been less clear for invasive cervical cancer. Nonetheless, the incidence of several additional cancers, the non-AIDS defining cancers, has also increased statistically in Human Immunodeficiency Virus (HIV) infected individuals. |
| PL7.3 | [PL7.3] IMPACT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON THE OUTCOME OF HIV-ASSOCIATED NON-HODGKIN LYMPHOMA AND HODGKIN’S DISEASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL7.3 M Simcock, M Blasko, U Karrer, M Pless, P Tarr, B Hirschel, H Furrer, M Rickenbach, H Guenthard, P Sendi, E Bernasconi, P Vernazza, M Battegay, The Swiss HIV Cohort Study HAART increased OS by 22 months in HIV-related NHL and HD, with increased PFS also. Use of CHOP chemotherapy greatly reduces the risk of lymphoma progression and ultimately death. |
| PL8 - HIV-related Infections, Co-infections and Malignancies II |
|
| PL8.1 | [PL8.1] TREATMENT INTERRUPTIONS: WHERE ARE WE? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.1 Bernard Hirschel In conclusion, SMART’s results imply that STIs will always be associated with a slightly increased risk of AIDS-defining events and death. It stands to reason, however, that the shorter the STI, and the higher the CD4 count, the lower the excess risk. At some point, the cost of continuing treatment at high CD4 counts counterbalances the increased risk of interrupting it. Where is that point? Economical, political and psychological, rather than medical arguments will decide. |
| PL8.2 | [PL8.2] ACCEPTABILITY OF A STRUCTURED TREATMENT INTERRUPTION (STI) STRATEGY OF 12 WEEK CYCLES ON AND OFF ART IN PATIENTS IN THE DART TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.2 D Tumukunde, G Lillian, S Mutsai, R Nalumenya, J Komunyena, D Nsibambi, M Machingura, A Burke, on behalf of the DART Trial Team Although the STI strategy in DART was associated with a 2.6-fold increase in disease progression compared to CT, the absolute rate was low with the majority (92%) able to take ART intermittently without developing WHO 4 events. Around 40% of patients reported problems with STI: but a sizeable minority (around 30%) perceived fixed cycle STIs as having some advantages. Identification of predictors of poor response to STI and strategies with lower risks remains important. |
| PL8.3 | [PL8.3] ARE TREATMENT INTERRUPTIONS ASSOCIATED WITH HIGHER VIRAL REBOUND RATES IN PATIENTS WITH VIRAL SUPPRESSION? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.3 L K Bansi, A A Benzie, C A Sabin, A N Phillips Previous episodes of treatment interruptions do not appear to be associated with viral rebound. Analyses are underway to determine whether the type of regimen interrupted and restarted has impact on viral rebound. |
| PL8.4 | [PL8.4] NEW PARADIGMS OF CARE: CUTTING CORNERS AND MAINTAINING STANDARDS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL8.4 Paul Benn The re-evaluation of existing roles of health care providers within HIV services, including developing extended roles and non-medical prescribing, has been key. In addition, the successful implementation of several service innovations, including telephone consultations and e-mail communication, has afforded individuals more choice and have proven to be effective without compromising quality of care. |
| PL9 - Adverse Events I |
|
| PL9.1 | [PL9.1] DRUG HYPERSENSITIVITY IN THE SETTING OF HIV: PATHOGENESIS AND MANAGEMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.1 Simon Mallal Abstract not available. |
| PL9.2 | [PL9.2] HLA-B5701 TESTING AND ABACAVIR HYPERSENSITIVITY: A SINGLE CENTRE EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.2 Laura Waters, Andrea Gritz, Desmond Maitland, Mark Nelson Prospective HLA-B5701 testing has proven to be useful in reducing the rate of ABC discontinuation secondary to suspected HSR; historically approximately 7% have discontinued therapy for possible HSR reduced to 1.8% since the introduction of prospective HLA testing. Our results highlight the necessity for maintaining clinical suspicion despite negative HLA testing. |
| PL9.3 | [PL9.3] SEXUAL DISSATISFACTION IN ASSOCIATION WITH COMBINATION ANTIVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.3 Bob Colebunders Sexual dissatisfaction (SD), especially loss of libido, is present in a very high number of men and women with HIV infection. HIV-discrimination and disturbing adverse events such as lipodystrophy due to HIV-treatment have been reported to be associated with SD. |
| PL9.4 | [PL9.4] Predict, avoid and manage side-effects and adverse events of ART: the needs of people living with HIV/AIDS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.4 Luis Mendao Treatments for HIV/AIDS continue to have a prevalence of associated adverse events (AE) and side-effects (SE) that negatively impact on the adherence, quality of life of patients and health of affected people. We need to improve the reporting, knowledge and spread of information to doctors and patients using a range of processes. |
| PL9.5 | [PL9.5] Relationship between use of stavudine and diabetes mellitus Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.5 S De Wit, CA Sabin, R Weber, SW Worm, P Reiss, R Thiebaut, W El-Sadr, A D'Arminio Monforte, E Fontas, MG Law, AN Phillips, N Friis-Moeller, JD Lundgren Stavudine is significantly associated with DM after adjustment for risk factors for DM and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that stavudine potentially directly contributes to insulin resistance, rather than through lipodystrophy. |
| PL9.6 | [PL9.6] MITOCHONDRIAL DNA (mtDNA) DEPLETION IS PRESENT IN OOCYTES OF HIV-INFECTED ANTIRETROVIRAL-TREATED INFERTILE WOMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL9.6 G Garrabou, O Coll, M Durban, S Lopez, R Vidal, A Suy, S Hernandez, F Cardellach, D Mataro, O Miro Oocytes of infertile HIV-infected ARV-treated women show decreased mtDNA and this could explain their poor reproductive outcome. |
| PL10 - Paediatric Infection |
|
| PL10.1 | [PL10.1] HIV+ teenagers: transfer to adult clinics Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL10.1 Alexandra Peltier Early disclosure (if possible before puberty), support groups and specific counseling should be offered to teenagers. Training and reference centers should supervise and study more deeply special needs for an effective transition between pediatric and adult clinics and between teenage and adult life in order to avoid failure to treatment and loss for follow up. |
| PL10.2 | [PL10.2] FORMULATION, DOSING AND ART STRATEGIES FOR CHILDREN WITH HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL10.2 Diana Gibb Effective prevention of mother-to-child HIV transmission, including testing, perinatal ARV prophylaxis, and safe alternatives to breastfeeding, have resulted in few births of vertically HIV-infected babies in well-resourced countries since 2000. Thus, in Europe and US, paediatric HIV-infected cohorts are older children entering adolescence who have either received previous mono and dual ART prior to HAART, or are newly diagnosed having recently moved to live in these countries. |
| PL12 - Adverse Events II |
|
| PL12.1 | [PL12.1] REDUCING CARDIOVASCULAR RISK IN THE SETTING OF HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.1 Judith Currier Data from observational studies suggest that HIV infection, and to some extent HIV treatments, may contribute to increasing cardiovascular risk. Although the specific contributions of traditional risk factors and HIV therapy to cardiovascular risk remain incompletely defined, it is critical that providers determine the optimal means to reduce long-term cardiovascular risk in this population. |
| PL12.2 | [PL12.2] EFFECT OF INTERVENTIONS TO IMPROVE DYSLIPIDAEMIA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.2 M vd Valk, N Friis-Møller, C Sabin, F Dabis, A D'Arminio Monforte, R Weber, S Worm, W El-Sadr, S de Wit, C Pradier, O Kirk, M Law, A Philips, J Lundgren, P Reiss At 1 year, reductions in TC, LDL, TG and TC/HDL were significant for both the LLT and SWITCH groups, whereas a significant HDL rise was only seen in those switching. The effect of the interventions on TC/HDL ratio was similar. Changes were also observed in controls, suggesting some regression to the mean effect, or possible selection of those in whom intervention was withheld in view of declining lipid values. |
| PL12.3 | [PL12.3] THE MANAGEMENT OF LIPOATROPHY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL12.3 Jussi Sutinen For any patient with signs of LA, a thymidine analogue (stavudine, zidovudine) should be replaced either by abacavir or tenofovir if the switch is considered virologically safe. Switching away from a protease inhibitor does not correct LA. |
| PL13- Hot Topics and Late Breakers |
|
| PL13.1 | [PL13.1] THE PRESCO TRIAL: ROLE OF EXTENDED DURATION OF THERAPY WITH PEGYLATED INTERFERON ALFA-2A PLUS WEIGHT-BASED RIBAVIRIN DOSE IN 389 HCV/HIV CO-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.1 Marina Nuñez, Celia Miralles, Miguel A Berdún, Elena Losada, Koldo Aguirrebengoa, Antonio Ocampo, Piedad Arazo, Manuel Cervantes, Ignacio de los Santos, Isabel San Joaquín, Santiago Echeverria, María J Galindo, Victor Asensi, Pablo Barreiro, Julio Sola, Juan J Hernandez-Burruezo, Josep M Guardiola, Vincent Soriano, on behalf of the PRESCO Study Group PRESCO is the largest trial conducted so far in coinfected patients using pegIFN plus RBV. The use of 1000-1200 mg/day of RBV was relatviely safe and provided SVR in nearly half of HCV/HIV-coinfected patients, twice higher in HCV-2/3 than HCV-1/4 carriers. Both the use of higher RBV doses and extended duration of therapy most likely explained the better responses in this study compared to prior trials conducted in coinfected patients. |
| PL13.2 | [PL13.2] PREDICTORS OF CREATININE (CR) INCREASE AND DRUG DISCONTINUATION IN PATIENTS RECEIVING TENOFOVIR DF (TDF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.2 M Harris, R Joy, N Zalunardo, R Werb, B Yip, R Hogg, J Montaner Among patients taking TDF, Cr elevation and TDF discontinuation are associated with concomitant use of ddI (but not boosted PIs), and with lower CD4, as previously shown. |
| PL13.3 | [PL13.3] IMPACT OF A LOPINAVIR/RITONAVIR (LPV/r) MONOTHERAPY ON SELF-REPORTED SIDE EFFECTS AND GLOBAL HEALTH PERCEPTION AMONG ANTIRETROVIRAL-NAÏVE PATIENTS: 48-WEEK ANALYSIS OF THE MONARK TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.3 B Spire, F Marcellin, I Cohen Codar, B Knysz, C Lascoux, M A Valantin, M Norton, P NgoVan, J F Delfraissy Patients’ quality of life, estimated by the number of self-reported side effects and perception of global health was better with LPV/r monotherapy when compared with a triple regimen of LPV/r+AZT/3TC. Further exploration of LPV/r monotherapy is warranted. |
| PL13.4 | [PL13.4] EFFICACY AND SAFETY OF TWO DOSES OF TIPRANAVIR/RITONAVIR VERSUS LOPINAVIR/RITONAVIR-BASED THERAPY IN ANTIRETROVIRAL-NAÏVE PATIENTS: RESULTS OF BI 1182.33 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. PL13.4 D Cooper, R Zajdenverg, K Ruxrungtham, R L Chavez The TPV-200 arm was closed due to higher rate of G3/4 ALT elevations. While non-inferiority was achieved with data collected up to Week 48 in all arms, TPV-100 was no longer non-inferior using Week 60 data from all patients due to a higher discontinuation rate based on a less favourable tolerability profile. |
| Posters |
|
| Treatment Strategies - Naïve |
|
| P1 | [P1] ONCE-DAILY BOOSTED FOSAMPRENAVIR (FPV/r) OR ATAZANAVIR (ATV/r) WITH TENOFOVIR (TDF)/EMTRICITABINE (FTC) IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS: 24-WEEK RESULTS FROM COL103952 (ALERT) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P1 K Smith, W Weinberg, E DeJesus, M Fischl, Q Liao, L Ross, K Pappa, T Lancaster Both regimens studied demonstrated a high rate of virologic suppression with similar lipids through 24 wks. |
| P2 | [P2] EFFICACY AND SAFETY OF ONCE-DAILY BOOSTED FOSAMPRENAVIR/RITONAVIR (FPV/r) WITH ABACAVIR (ABC)/LAMIVUDINE (3TC) FIXED DOSE COMBINATION IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS: 24-WEEK RESULTS FROM COL100758 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P2 C Hicks, E DeJesus, L Sloan, M Sension, D Wohl, Q Liao, I Gray, T Lancaster Data suggest a high rate of virologic suppression through 24 wks for FPV/r 1400mg/100mg QD. These results should be interpreted with caution until full data through 48 wks are available. |
| P3 | [P3] DOES GENDER OR ETHNICITY INFLUENCE TREATMENT OUTCOMES IN ANTIRETROVIRAL NAÏVE PATIENTS COMMENCING NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) BASED HAART? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P3 NT Annan, S Mandalia, M Bower, BG Gazzard, MR Nelson We have shown in a large NNRTI-experienced cohort that although in the univariate analysis females commencing HAART containing NVP are more likely than males to achieve VS, this association was not reproduced in the multivariable model. We found no association between ethnicity and either VS or TF. |
| P4 | [P4] EFAVIRENZ (EFV) VS. LOPINAVIT/RITONAVIR (LPV/R)-BASED COMBINED ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS FROM THE SPANISH VACH COHORT: THE SUSKA STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P4 Pere Domingo, Ramon Teira, Ignacio Suarez-Lozano, Jose Lopez-Aldeguer, Enric Pedrol Our study suggests that EFV-based cART has a longer durability than a LPV/r-based regime in naïve HIV and VHC co-infected patients. |
| P5 | [P5] LONG-TERM FOLLOW-UP OF IMANI I: PILOT STUDY OF THE SAFETY AND EFFICACY OF LOPINAVIR/RITONAVIR (LPV/R) AS SINGLE AGENT THERAPY (SAT) IN HIV-1 ANTIRETROVIRAL (ARV)-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P5 Joseph C Gathe, Jr., Carl Mayberry, Bernie Miguel, John Nemecek Follow-up of IMANI I, the longest followed cohort of ARV-naïve pts. on SAT therapy, reveal: 17/18 pts. on SAT had VL <50 at last evaluable time point, no genotypic/phenotypic resistance in any subject at any time point, intensified pts. (n=2) both remained virologically suppressed VL<50, one failing pt. was due to lack of LPV/r access, no significant toxicity was seen/no lipid lowering agents were prescribed, and continued success with switch to LPV/r tablets. These promising long-term results strongly support larger study of LPV/r as an option to triple therapy HAART in ARV-naïve pts. |
| P6 | [P6] EFFICACY AND SAFETY OF TENOFOVIR DF (TDF), EMTRICITABINE (FTC) AND EFAVIRENZ (EFV) COMPARED TO FIXED DOSE ZIDOVUDINE/LAMIVUDINE (CBV) AND EFV THROUGH 96 WEEKS IN ANTIRETROVIRAL TREATMENT-NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P6 A Pozniak, J Gallant, E DeJesus, J Arribas, B Gazzard, D McColl, J Enejosa, A Cheng Through Wk 96, significantly more pts on TDF+FTC+EFV achieved HIV RNA<400 c/mL and had higher CD4 cell increase from baseline. More pts in CBV arm discontinued study regimen due to adverse events. Limb fat was significantly higher in TDF+FTC arm. |
| P7 | [P7] SIMILAR ANTIVIRAL EFFICACY AND TOLERABILITY BETWEEN EFAVIRENZ AND LOPINAVIR/RITONAVIR, ADMINISTERED WITH ABACAVIR/LAMIVUDINE (KIVEXA), IN NAÏVE PATIENTS: A MULTICENTRE, RANDOMIZED STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P7 Patricia Echeverria, Giampiero Carosi, Juan Galves, Isabel Bravo, Raquel Lopez, Bonaventura Clotet EFV demonstrated comparable antiviral efficacy and safety to LPV/r over 24 wk administered with ABC/3TC (Kivexa). Hypersensitivity reaction was higher in EFV-group, probably due to the ABV and EFV combination. |
| P8 | [P8] STUDY OF THE EVOLUTION AND SURVIVAL RATE OF A COHORT (COHORT OMEGA) OF PATIENTS WITH A LATE STAGE OF HIV INFECTION. EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY (4 YEARS LATER) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P8 Rosario Palacios, Mercedes Gonzalez, Josefa Ruiz, Manuel Marquez In spite of the advanced stage of HIV infection at diagnosis, the outcome of this cohort is very good and the long-term survival is high. Mortality mainly occurs in the first months. The immunovirologic response is very good, with few new opportunistic events, few adverse events and few virologic failure. |
| P9 | [P9] SIMILAR VIROLOGIC AND IMMUNOLOGIC RESPONSE TO EFAVIRENZ OR LOPINAVIR/RITONAVIR-BASED HAART IN A LARGE COHORT OF ANTIRETROVIRAL-NAÏVE PATIENTS WITH ADVANCED HIV INFECTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P9 F Pulido, J Arribas, S Moreno, J Gatell, B Vendrell, O Serrano After adjusting for differences in BL characteristics in this retrospective cohort study, EFV showed similar efficacy to LPV/r in Tx naïve severely immunodepressed Pts with less D/C due to intolerance. |
| P10 | [P10] ONCE-DAILY (QD) ABACAVIR (ABC)/LAMIVUDINE (3TC) AND RITONAVIR-BOOSTED ATAZANAVIR (ATV/R) IN ANTIRETROVIRAL NAÏVE HIV-1 INFECTED SUBJECTS: 24-WEEK ANALYSIS FROM COL102060 (SHARE) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P10 R Elion, E DeJesus, M Sension, D Berger, W Towner, G Richmond, L Yau, B Ha A high rate of virologic suppression was observed through 24 weeks. The development of hypertriglyceridemia was observed possibly due to ritonavir-boosting. |
| P11 | [P11] EFFECTIVENESS OF DIDANOSINE, LAMIVUDINE, EFAVIRENZ AND ZIDOVUDINE, LAMIVUDINA, EFAVIRENZ IN NAIVE HIV-INFECTED PATIENTS FROM THE SPANISH VACH COHORT (QUOVIDES STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P11 Ignacio Suarez-Lozano, Esteban Ribera Our data suggest that, in real clinical practice, ddI and 3TC, as a backbone in Efavirenz based cART, has the same durability than the recommended backbone of ZDV and 3TC in HIV-infected and in HCV co-infected naïve patients. |
| P12 | [P12] RESPONSE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN NAÏVE PATIENTS: THE NEWCASTLE EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P12 B Payne, J Matthew, A Foster, D Burns, A Tromans, D Price, M Schmid, M Snow, E Ong Our study confirms the potency and tolerability of HAART, particularly NNRTI based regimes, for antiretroviral naïve patients. Excellent virological suppression, comparable with clinical trial outcomes, is achievable in the clinic setting. |
| P13 | [P13] SUSTAINED VIROLOGIC AND IMMUNOLOGIC RESPONSE OVER 180 WEEKS IN ANTIRETROVIRAL THERAPY (ART)-NAÏVE SUBJECTS RECEIVING FOSAMPRENAVIR/RITONAVIR (FPV/R) QD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P13 N Bellos, N Clumeck, G Bleiber, S Tomkins, F Xu, H Garges Long-term treatment with FPV/r QD in ART-naïve subjects resulted in sustained virologic suppression, continued immunologic improvement, few subjects with new drug-related AEs and rare development of resistance. |
| P14 | [P14] COST-EFFECTIVENESS ANALYSIS OF TENOFOVIR/EMTRICITABINE AND ABACAVIR/LAMIVUDINE IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P14 John Borrill, Ruairi A O'Donnell, Claudio Avila, Francois Everhard, Michelle E Orme TDF/FTC is cost-effective compared to CBV and offers more convenient dosing. ABC/3TC is unlikely to be cost-effective versus CBV given that it was not shown to be more efficacious than CBV. |
| P15 | [P15] COMPARISON OF SINGLE AND BOOSTED-PROTEASE-INHIBITOR (PI) VERSUS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) CONTAINING REGIMENS IN PREVIOUSLY ANTIRETROVIRAL NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P15 A Mocroft, O Kirk, A Horban, N Clumeck, H J Stellbrink, A d'Arminio Monforte, K Zilmer, J Gatell, A N Phillips, J D Lundgren, the EuroSIDA study group Compared to patients starting a NNRTI regimen, patients starting a single-PI regimen were less likely to be virologically suppressed at 3 years after starting cART. These results from an observational setting are consistent with those from INITIO, a randomised trial. Ultimately, clinical outcome will be the measure of efficacy of cART regimens, which requires the follow-up of large numbers of patients over many years. |
| P16 | [P16] ABC/3TC IN COMBINATION WITH A BOOSTED PI IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P16 Andreas Carganico, Stephan Dupke, Bettina Hintsche, Frank Schlote The combination of ABC/3TC and a boosted PI is a potent and safe treatment option in therapy naïve patients in a clinical setting. |
| P17 | [P17] FOSAMPRENAVIR BOOSTED WITH A SINGLE 100 MG CAPSULE OF RITONAVIR AS PART OF A ONCE DAILY FIRST LINE REGIMEN IN NAÏVE PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P17 Stephane De Wit, Benedicte Poll, Coca Necsoi, Nathan Clumeck The combination of Fosamprenavir boosted with a single 100 mg dose of Ritonavir +Tenofovir + Lamivudine (or Emtricitabine) is a convenient, highly effective, well tolerated once daily first line regimen, with little impact on lipid profile. The use of Fosamprenavir boosted with a single daily Ritonavir capsule should be further evaluated. |
| P18 | [P18] INDUCTION/MAINTENANCE STRATEGY WITH ATAZANAVIR/RITONAVIR Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P18 Douglas J Ward, Charles Fiorentino An induction / maintenance strategy of ATV/r going to ATV provides a potent, well tolerated treatment regimen with high rates of long term viral suppression and minimal toxicity in treatment naïve and select treatment experienced patients. |
| P19 | [P19] SUCCESS OF AN INDUCTION-MAINTENANCE STRATEGY USING BOOSTED FOSAMPRENAVIR PLUS ZIDOVUDINE AND LAMIVUDINE FOR TREATING HIV-1 INFECTED DRUG-NAÏVE SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P19 P Di Vincenzo, O Viganò, M Galazzi, L Meroni, M Moroni, M Galli, S Rusconi Induction-maintenance therapy with FPV/RTV resulted in sustained viral suppression and continued immunological benefit. CD4/CD8 apoptosis decreased over-time mirroring an amelioration of the immune system. Antiretroviral therapy including an induction phase with a potent PI followed by a maintenance simplified therapy with EFV has been well tolerated in naïve patients. |
| P20 | [P20] NNRTIs-BASED HAART IN CLINICAL PRACTICE. A RETROSPECTIVE STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P20 Benedetto M Celesia, Luciano Nigro, Sergio Mavilla, Rosario La Rosa, Arturo Montineri, Monica Nicotra, Rosario Russo EFV seems to induce better immunoreconstitution and higher rate of VL suppression than NVP although at baseline subjects treated with EFV are more immunocompromised. In naïve subjects the two drugs show similar metabolic and hepatotoxic profile. |
| P21 | [P21] THE VeLLA STUDY: VIH EN LATINOS/LATINAS EN LOS ANGELES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P21 Daniel D Pearce, Felix F Carpio, Bill Guyer, Debra Johnson In this small pilot study, a once-daily regimen of TVD and ATV/r was safe, well tolerated and associated with positive virologic and immunologic effects in treatment-naïve Latino patients. Concerns about the efficacy or renal toxicity of this regimen were not supported in this trial. |
| Treatment Strategies - Experienced |
|
| P22 | [P22] VIROLOGIC RESPONSE FOLLOWING DISCONTINUATION OF LAMIVUDINE (3TC) AMONG PATIENTS WITH 3TC-RESISTANT HIV AND WITH ≥ 2 ACTIVE DRUGS IN THE HAART REGIMEN (CTN 189) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P22 M Harris, R Sandre, E Yu, A Thorne, J Singer, J Montaner Our preliminary results indicate that discontinuing 3TC in the setting of M184V/I is not associated with a loss of VL control among patients receiving ≥3 other ARVs of which ≥2 were active (excluding 3TC). |
| P23 | [P23] COMBINED ANALYSIS OF RESIST 96 WEEK DATA: DURABILITY AND EFFICACY OF TIPRANAVIR/R IN TREATMENT EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P23 B Gazzard, A Antinori, C Cheli These 96 week results confirm the durable superiority of TPV/r vs. CPI/r regimens in HTE patients. Combining TPV/r with an active ARV, e.g. ENF, resulted in a greater virologic response rate. |
| P24 | [P24] WEEK 48 EFFICACY OF TPV/R TREATMENT IS ENHANCED IN PATIENTS WITH HIGHER NUMBERS OF GENOTYPICALLY AVAILABLE BACKGROUND DRUGS IN RESIST 1 AND 2 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P24 A Lazzarin, J Feinberg, M Kraft, D Hall TPV/r provides superior efficacy compared with CPI/r through 48 weeks. Treatment responses to TPV/r regimens improved with increasing numbers of active OBR ARVs. |
| P25 | [P25] HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF PATIENTS TREATED IN RESIST Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P25 A W Wu, I Huang, H Thijs, H W Finnern, M Kraft, J C Gathe, D L Fairclough Despite a higher incidence of treatment-related AEs, HRQOL in TPV/r patients was stable or improved in comparison to treatment with CPI/r. |
| P26 | [P26] ARV-EXPERIENCED PATIENTS RECEIVING TDF + ddI IN THE RESIST STUDIES HAD A REDUCED CD4 RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P26 B Clotet, E Negredo, PM Girard, M Youle, D Neubacher, J Leith RESIST patients receiving TDF and ddI had similar virologic responses but reduced CD4 responses versus patients taking TDF without ddI. |
| P27 | [P27] RESPONSE TO MONO-CLASS NUCLEOSIDE REGIMEN OF TENOFOVIR DF + TRIZIVIR IN ANTIRETROVIRAL-EXPERIENCED PATIENTS: 48 WEEK RESULTS AND PREDICTORS OF RESPONSE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P27 B Dauer, P Khaykin, P Gute, S Klauke, M Stuermer, S Staszewski Pts on a failing NRTI-only regimen showed virologic response after TDF-intensification. Patients who failed virologically did so early. BSL VL <5000 copies was a significant predictor for response. Mono-class TDF+TZV therapy showed increasing efficacy even after 24 weeks which was maintained out to 48 weeks. |
| P28 | [P28] TMC114/r HAS TOLERABILITY AND EFFICACY BENEFITS FOR TREATMENT-EXPERIENCED PATIENTS COMPARED WITH CONTROL PIS: OVERVIEW OF THE POWER TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P28 J Rockstroh, N Clumeck, S Spinosa-Guzman, E De Paepe, E Lefebvre TMC114/r shows an improvement in gastrointestinal tolerability compared with CPIs. This may be of benefit to treatment-experienced pts. |
| P29 | [P29] TMC114/r PROVIDES GREATER EFFICACY BENEFITS VERSUS CONTROL PROTEASE INHIBITOR(S), REGARDLESS OF THE PROTEASE INHIBITOR OR SENSITIVITY TO THE PROTEASE INHIBITOR: POWER 1 AND 2 TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P29 E Lefebvre, S De Meyer, E De Paepe, A Hill TMC114/r 600/100mg bid showed efficacy benefits over each CPI used, regardless of the sensitivity to the PI. |
| P30 | [P30] A PILOT 48 WEEK STUDY OF ONCE DAILY (180MG QD) VS TWICE DAILY (90MG BID) ENFUVIRTIDE (ENF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P30 D Wright, A Rodriguez, E Godofsky, S Walmsley, E Labriola-Tompkins, A Shikhman, E Tucker, Y-Y Chiu, J Chung, L Rowell, N Graham, M Salgo Despite somewhat better adherence on QD, both ENF QD and BID appeared similar, although the study was not designed or powered to assess non-inferiority of QD dosing. Further studies are warranted. |
| P31 | [P31] DURABILITY OF HIV RNA ENDPOINTS IN TREATMENT EXPERIENCED PATIENTS – ANALYSIS OF POWER, RESIST AND TORO TRIALS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P31 Andrew Hill, Diego Miralles, Tony Vangeneugden, Eric Lefebvre Although 1 log HIV RNA log reduction endpoint has been used to evaluate efficacy in patients with poor therapeutic options, the HIV RNA 50 copy endpoint is more likely to be sustained in longer-term follow-up, and should become the primary efficacy parameter for new pivotal trials of both treatment naïve and experienced patients. |
| P32 | [P32] SIMPLIFICATION TO EFAVIRENZ + ABACAVIR/LAMIVUDINE (KIVEXA) IN PREVIOUSLY SUPPRESSED HIV-INFECTED PATIENTS COMPARED WITH OTHER CONVENTIONAL REGIMENS OF 2 NUCLEOSIDES + EFAVIRENZ: 6-MONTHS OF FOLLOW-UP Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P32 Patricia Echeverria, Javier de la Torre, Juan Pasquau, Jose Sanz, Isabel Bravo, Raquel Lopez, Bonaventura Clotet, Eugenia Negredo The combination ABC/3TC(Kivexa)+EFV is a good alternative as a simplification regimen due to its virological and immunological effectiveness and good tolerability. |
| P33 | [P33] COMBINATION ANTIRETROVIRAL THERAPY WITHOUT A NUCLEOSIDE ANALOGUE: EXPERIENCE FROM 334 PATIENTS IN THREE COHORTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P33 A Calmy, K Petoumenos, C Lewden, M Law, F Bocquentin, K Hesse, D Cooper, A Carr, F Bonnet In these antiretroviral-experienced patients, NRTI-sparing therapy appeared to have satisfactory virological and immunological efficacy. However, hyperlipidemia was frequent and requires monitoring of cardiovascular risk-factors. |
| P34 | [P34] TENOFOVIR PLUS DIDANOSINE BACKBONE IN HIV-PATIENTS FAILING HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P34 M Bongiovanni, N Gianotti, E Chiesa, P Nasta, A Capetti, P Cicconi, P Marconi, G Rizzardini, T Quirino, A Antinori, A Matti, C Torti, A Castagna, A d'Arminio HAART containing TDF/ddI are associated with a good virologic and immunologic outcome when their choice is driven by a genotypic resistance test. |
| P35 | [P35] SAQUINAVIR IN DOUBLE PROTEASE INHIBITOR REGIMENS BOOSTED WITH RITONAVIR (R) – RESULTS OF THE AROMA-COHORT: COMPARISON OF SAQUINAVIR/ATAZANAVIR/r VERSUS SAQUINAVIR/LOPINAVIR/r Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P35 Axel Baumgarten Both saquinavir containing double PI regimens were effective and well tolerated. Subgroup analyses did not indicate an additional benefit of the optimized background. The data support the use of SQV in boosted double PI regimens. |
| P36 | [P36] CLINICAL EXPERIENCE WITH NEVIRAPINE: A COHORT ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P36 Franco Maggiolo, Claudio Arici, Monica Airoldi, Veronica Ravasio, Diego Ripamonti NVP-based therapies are still widely used and are a cornerstone of HAART in developing Countries. Our data indicate that these regimens may be effective for a long period of time and that tolerability of this drug is high. |
| P37 | [P37] NEVIRAPINE TWICE-DAILY VERSUS ONCE-DAILY AS A SIMPLIFICATION STRATEGY AFTER A SUCCESSFUL PROTEASE INHIBITORS-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P37 Massimo Giola, Daniela Dalla Gasperina, Cristina Basilico, Leonardo Tomasello, Laura Lazzaroni, Paolo Grossi Our study, at the interim analysis at 24 weeks, did not show a statistically significant difference between NVP BID and OD in the setting of simplification after a successful PI-based HAART. However, a trend towards a better tolerability of NVP BID needs to be confirmed at 48 weeks and probably in larger studies. |
| P38 | [P38] ATAZANAVIR/RITONAVIR IN COMBINATION WITH NEVIRAPINE AS A NUCLEOSIDE-SPARING STRATEGY IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED SUBJECTS (NEVATA STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P38 A M Cattelan, M Trevenzoli, S Cavinato, I Cerbaro, F Salin, F Adorni, S G Parisi, G Palu Dual therapy with ATV/RTV plus NVP is potent and safe as standard-of-care HAART at week 24 of follow-up. These preliminary data suggest a significant improvement in triglyceride profile and in HDL-cholesterol level in the nucleoside-sparing regimen. |
| P39 | [P39] EFFICACY AND SAFETY OF TELZIR™ IN HIV PATIENTS: RESULTS FROM THE SPANISH EXPANDED ACCESS PROGRAM (EAP) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P39 M Sanchez-Conde, MJ Prez-Elias, F Blanco, J Mallolas, B Clotet, C Alonso, J Galindo, I Luque, F Rodriguez-Alcantara In this EAP, fosamprenavir/ritonavir BID was well tolerated and provided therapeutic benefit to ART-experienced subjects including those heavily pre-treated, with high degree of co-morbidities and/or inmunosuppression. |
| P40 | [P40] INTER-COUNTRY VARIATION IN PHYSICIAN PERSPECTIVES OF ENFUVIRTIDE (ENF) PRESCRIBING Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P40 R Horne, V Cooper, G Gellaitry Significant inter-country differences exist in physician attitudes to Rxing injectable ARVs. The country-specific barriers identified may assist in designing targeted interventions to help optimize use of injectable ARVs in ARV-experienced patients. |
| P41 | [P41] PATIENTS' AND PHYSICIANS’ PERCEPTIONS TOWARDS SUBCUTANEOUS TREATMENT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P41 H Knobel, C Fumaz, A Segador, A Lorenzo, J Gonzalez, M Garcia Pulgar, N Perulero Physicians perceive that SC may affect daily life situations and psychological patient’s life in greater extent than patient himself. |
| P42 | [P42] EFFICACY AND SAFETY OF LOPINAVIR/R AND ATAZANAVIR WITHOUT A NUCLEOSIDE BACKBONE IN ANTIRETROVIRAL THERAPY EXPERIENCED HIV-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P42 David A Parks, Harold C Jennings, Christopher W Taylor, Jean M Tschampa The combination of LPV/r 400/100mg bid + ATV 300mg qd was shown to be efficacious and well tolerated. There were no virologic failures and the mean CD4+ T-cells increased. No subjects experienced grade III/IV adverse events. Although the study population was small, these results suggest that this dual PI combination is a safe and effective nucleoside sparing regimen, further studies are warranted. |
| P43 | [P43] STUDY ON THE EFFICACY OF REDUCED-DOSE STAVUDINE IN PATIENTS RECEIVING RESCUE THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P43 Enric Pedrol, Alex Almuedo, Esther Ferrer, Pedro García, Elisabet Deig In this study, reduced-dose stavudine used in rescue therapy does not compromise immuno-virological efficacy and its safety profile is good. |
| P44 | [P44] CHARACTERISTICS OF HIV INFECTED PATIENTS ELIGIBLE TO PARTICIPATE IN THE SMART STUDY IN GLASGOW Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P44 L McLean, R Fox Our results show that there are important differences between patients who are participating in the SMART study and those who are not. These differences and the reasons identified for non-participation would be helpful in designing any future similiar study. |
| P45 | [P45] TREATMENT OF ANTIRETROVIRAL EXPERIENCED, ENFUVIRTIDE NAÏVE, ADVANCED HIV PATIENTS WITH A BOOSTED TIPRANAVIR – ENFUVIRTIDE BASED REGIMEN IN CLINICAL PRACTICE: 24-WEEK RESULTS OF AN ITALIAN COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P45 Giustino Parruti, Augusta Consorte, Giuseppina Placido, Alessandro Pieri, Adriana Agostinone, Luciana Alterio, Rocco V Graziani, Giuseppe D'Amico Our experience adds evidence that TPV/r-ENF based regimens may induce remarkable benefits in ordinary clinical settings. Lower TPV mutation scores were associated with better and prompter control of viral replication. |
| P46 | [P46] A STUDY ON THE PERFORMANCE OF COMBINATION OF KALETRA® AND SAQUINAVIR TWICE-DAILY REGIMEN ON A GROUP OF ANTIRETROVIRAL THERAPY EXPERIENCED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P46 Kaveh Manavi, Collette Burns, Alexander McMillan Kaletra®/ saquinavir may result in viral suppression and significant increase in CD4+ T-cell count in the majority of patients without PI mutations. Further investigation on the potency and the frequency of all possible side effects of this regimen is required. |
| P47 | [P47] ENFUVIRTIDE + NRTIs FOR THE TREATMENT OF HIV INFECTED PATIENTS WITH CONCURRENT ACTIVE MYCOBACTERIAL INFECTION: A PILOT EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P47 Clotilde Allavena, Charlotte Biron, Marie Pierre Cossevin, David Boutoille, Pascale Bemer, Francois Raffi, Eric Billaud Given the high prevalence of active mycobacterial infection at low CD4 cell counts, and the need to include rifamycin in the treatment regimen, controlled studies to assess cost-benefit of ARV therapy with or without ENF are needed. |
| P48 | [P48] CD4+ T-CELL EVOLUTION AFTER TENOFOVIR/DIDANOSINE BACKBONE (TDF/ddI) IN PRESENCE OF UNDETECTABLE HIV-RNA Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P48 C Torti, G Lapadula, P Barreiro, V Soriano, S Mandalia, A De Silvestri, F Suter, F Maggiolo, A Antinori, F Antonucci, R Maserati, I El Hamad, P Pierotti, L Sighinolfi, G Migliorino, N Ladisa CD4+ T-cell loss was not seen in patients on TDF-ddI (low dose) for up to 24 months, after excluding the possible influence of positive HIV-RNA. Factors explaining inter-individual variability could explain blunted CD4 recoveries and/or paradoxical declines in former studies using higher doses of ddI and/or longer follow-ups. In the meantime, our results are reassuring about the safety of this combination in treatment simplification strategies. |
| P49 | [P49] CLINICALLY STABLE TREATMENT-EXPERIENCED ADULTS RECEIVING TENOFOVIR AND DIDANOSINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P49 Andrea Beltrame, Daniela Fenoglio, Paola Costa, Antonio Di Biagio, Francesco Vitale, Giovanni Cenderello, Giuseppe Ferrea, Claudio Viscoli, Andrea De Maria In HAART-experienced pts, the administration of ddI+TDF compared to ddI+3TC didn’t increase adverse effects or decreased efficacy, in the presence of conserved CD4+ T cell function. |
| P50 | [P50] STUDY OF CHANGES IN CD4 CELLS COUNT AFTER SWITCHING TENOFOVIR TO ABACAVIR OR TDF AND DIDANOSINE TO ABC+LAMIVUDINE IN PATIENTS WITH A ddI+TDF CONTAINING REGIMEN AND VIRAL SUPPRESSION (EUROPA STUDY): PRELIMINARY ANALYSIS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P50 E Pedrol, E Negredo, P Domingo, V Estrada, A Ocampo, J Flores, S Echevarria, A Terron, E Deig After 12w of treatment no statistically significant differences were found between arms, except for those pts that were treated with ABC+3TC. Then a longer follow-up will probably reveal if these differences exits between groups and decide what is the most suitable regimen in these pts. |
| P51 | [P51] COST-EFFECTIVENESS OF TMC114 (DARUNAVIR)/RITONAVIR COMPARED WITH CURRENTLY AVAILABLE PROTEASE INHIBITORS IN TREATMENT-EXPERIENCED HIV PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P51 J Mauskopf, A Brogan, E Smets, G Nuyts, S Martin TMC114/r is predicted to be a cost-effective therapy vs other currently available PIs and yields an average of 0.4 additional QALYs per treatment-experienced patient over 5 years. |
| P52 | [P52] COST-EFFECTIVENESS OF LOPINAVIR/R TABLETS COMPARED TO ATAZANAVIR + RITONAVIR IN ANTIRETROVIRAL EXPERIENCED PATIENTS IN THE UK, SPAIN, ITALY, AND FRANCE BASED ON RESULTS FROM BMS AI424-045 Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P52 Kit N Simpson, Walter Jones, Rukmini Rajagopalan, Brigitta Dietz The survival benefit of LPV/r is due to the differences in patients with VL suppressed to 50 copies/mL or below, while the economic benefit is due to both the lower cost of LPV/r and the savings incurred by slower rates of disease progressions. These estimates are robust to large variations in costs, but very sensitive to assumptions related to the viral rebound for patients with suppression to VL below 400 and below 50 copies/mL. |
| Treatment Strategies - Switch |
|
| P53 | [P53] IMPACT OF SWITCHING VIROLOGICALLY SUPPRESSED, HIV-INFECTED PATIENTS FROM FIXED-DOSE ZIDOVUDINE/LAMIVUDINE (CBV) TO FIXED-DOSE TENOFOVIR DF/EMTRICITABINE (TVD) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P53 Edwin DeJesus, Sheetal Sharma, Roberto Corales, Ramin Ebrahimi, Alvan Fisher, John Flaherty Pts switched to TVD+EFV maintained virologic suppression, and the regimen was well tolerated. Other benefits (↑Hb,CD4, ↓lipids) were noted. Pt satisfaction and adherence with the regimen were high. |
| P54 | [P54] SIMPLIFICATION FROM PROTEASE INHIBITOR (PI) TO EFAVIRENZ (EFV) BASED HAART IN VIROLOGICALLY SUPPRESSED HIV-INFECTED SUBJECTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P54 Calvin Cohen, Edwin DeJesus, Rafael Campo, Kristy Porter, Jen-Fue Maa, Daniel Seekins, Rozina Khanna Viral suppression was maintained and FAHI/IIRS-based QoL improved in subjects simplifying from PI to EFV-based HAART. EFV-based HAART was well tolerated, with few treatment-limiting AEs. |
| P55 | [P55] IMMUNOLOGICAL IMPROVEMENT IN PATIENTS WITH SUSTAINED LOW LEVEL VIREMIA-SLLV WHO SWITCH OR MAINTAIN A PARTIAL EFFECTIVE HAART (IMPROVE-MASTER STUDY) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P55 P Nasta, A Matti, F Gatti, F Castelnuovo, G Cocca, G Zoboli, MC Nigro, MC Colombo, C Calzetti, F Barchiesi, G Carosi, IMPROVE-Master Group CD4 cells decline was more pronounced in SLLV pts who switched HAART without obtain viral suppression, than in pts who maintain a partial effective regimen. The HAART switch in SLLV pts with stable CD4 cell count, should be consciously individualized. |
| P56 | [P56] SWITCHING A TOXICITY-CAUSING ANTIRETROVIRAL (ARV) TO ENFUVIRTIDE (ENF) IN PATIENTS WITH TREATMENT-LIMITING TOXICITIES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P56 M Stoll, M Muller, S Staszewski, M Gorgolas, J Portilla, A Streinu-Cercel, L Rowell, E Labriola-Tompkins, E Waalberg, M Salgo Med Hochschule, Hannover, Germany; Stuttgart, Germany; JW Goethe Substituting ENF for an ARV associated with a treatment-limiting toxicity led to toxicity improvements or resolution in the majority of these extensively pretreated patients with maintenance of viral suppression in many and immunological improvement in most. |
| P57 | [P57] COMPARING TREATMENT-SIMPLIFICATION STRATEGIES IN LONG-TERM OBSERVATION. PRELIMINARY RESULTS FROM SIMPLEF STUDY OF MASTER DATABASE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P57 A Antinori, P Lorenzini, M Zaccarelli, F Suter, F Maggiolo, G Cologni, F Castelnuovo, S Lo Caputo, L Sighinolfi, S Novati, G Migliorino, N Ladisa, G Carosi All simplification strategies showed similar efficacy in long-term. IDU and HCV+ predicted failure. Increasing risk of viral rebound by switch at high CD4 count could concern adherence. Simplifying to ABC from a potent PI, such as LPV/r, may increase the risk of failure. |
| P58 | [P58] THE RAINBOW COHORT: SUCCESSFUL INITIATION/SWITCH WITH/FROM THE NEW SAQUINAVIR 500MG FORMULATION – FIRST RESULTS FROM GERMANY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P58 H Knechten, T Lutz, G Knecht, A Haberl, A Carganico, F Glaessl, H Jaeger, A Tappe, E Wellmann, J Steinmueller These data suggest that patients can take advantage from switching to the convenient 500mg SQV FCT formulation without compromising virological and immunological control. The data support the use of boosted SQV as a first-line PI. |
| P59 | [P59] FINAL SAFETY AND EFFICACY ANALYSIS OF A RANDOMISED PILOT STUDY EVALUATING EARLY VERSUS LATE SWITCH FROM EFAVIRENZ TO NEVIRAPINE AS PART OF HAART: THE BI SWITCH STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P59 M Youle, U B Dragsted, D Podlekareva, C Smith, A Caroll, F Turner, M Johnson In this open-label, randomised, pilot study significant improvement in EFZ-related CNS AEs was seen at week 8 in pts switching to NVP at bl. No differences were seen in viral suppression, CD4 count or AEs between the study arms through week 24. |
| P60 | [P60] FTC IN AN OUTPATIENT GROUP: SWITCH OF A STABLE VIRUS-CONTROLLED ART TO A FTC-CONTAINING REGIMEN Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P60 Stefan Fenske, Thomas Buhk FTC as part of a combination therapy is a well tolerated and safe drug. There are no virological failures during the observation period. |
| P61 | [P61] VIROLOGIC SUPPRESSION IS MAINTAINED IN ANTIRETROVIRAL EXPERIENCED ADULTS WHO CHANGE FROM TENOFOVIR AND LAMIVUDINE TO TRUVADA, A ONCE DAILY FIXED-DOSE COMBINATION TABLET OF TENOFOVIR AND EMTRICITABINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P61 Amy E Colson, Calvin J Cohen, Claudia Martorell, Robert C Stevens, Karen McLaughlin Changing TDF and 3TC to Truvada maintained virologic suppression. Four wks after the change, 100% of participants found Truvada to be more convenient. |
| P62 | [P62] TOLERABILITY AND PREFERENCE OF LOPINAVIR/RITONAVIR (KALETRA) CAPSULES VERSUS TABLETS AS SINGLE AGENT THERAPY (IMANI-2) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P62 Joseph Gathe, Bryan Lipman, Bernie Miguel, Carl Mayberry, John Nemecek This is the first study to compare tolerability of LPV/r tablets to SGC in HIV + patients. Results indicate high tolerability, satisfaction and tablet preference. Low grade diarrhea on SGCs was absent post-switch. The absence of other ARVs allows direct measure of LPV/r tolerability without confounding therapy. |
| P63 | [P63] PROTEASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY SWITCH TO EFAVIRENZ-BASED REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P63 Pavel Khaykin, Schlomo Staszewski, Brenda Dauer, Amina Carlebach, Axel Mueller, Annette Haberl, Peter Gute, Gaby Knecht Modification of the HAART could achieve viral suppression if EFV was substituted for a PI or PI/r. However, some patients demonstrated adverse events or virologic failure. Most of patients who discontinued EFV had 2- or 3-class resistance in the treatment history. EFV is a proven component of standard-of-care in first-line HIV. Further investigation of EFV in patients after therapy failure of PI / PI/r containing regimens is warranted. |
| P64 | [P64] SWITCH TO A COMPLETELY ONCE DAILY REGIMEN CONTAINING EMTRICITABINE/TENOFOVIR-FIXED DOSE COMBINATION PLUS THIRD QD PARTNER: 24 WEEKS INTERIM ANALYSIS OF THE SONETT TRIAL Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P64 Lutwin Weitner, Stefan Fenske, Birger Kuhlmann, Matthias Freiwald, Ramin Ebrahimi, Lothar Gallo, Britta Ranneberg, Thomas Mertenskoetter, Keikawus Arasteh Results support switching from a stable CBV-containing HAART to a completely qd regimen of TVD plus third divergent partner given that virologic (< 50 c/mL) and immunologic control were maintained with the additional benefit of Hb increasing significantly. |
| Treatment Strategies - Treatment Interruptions |
|
| P65 | [P65] HIGH ACTIVITY ANTIRETROVIRAL THERAPY INTERRUPTIONS UNDER SUPERVISION: 5 YEARS FOLLOW UP Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P65 Marcial Delgado-Fernandez, Felipe Diez-Garcia, Ana Belen Lozano, Clara Natera-Kindelan, Joaquin Salas-Coronas, Rafael Cotos-Canca Drug holidays are feasible in concrete patients. |
| P66 | [P66] MORPHOLOGIC CHANGES 42 MONTHS AFTER ANTIRETROVIRAL TREATMENT INTERRUPTION Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P66 Eva Martinez, Carla Estany, Eugenia Negredo, Raquel Lopez, Ana Canton, Ana Sanmarti, Bonaventura Clotet HAART interruption was associated with a significant increase of weight and due to an increase of fat mass, mainly in trunk. The mild improvement of femur BMD with this strategy could suggest a negative impact of ARV therapy on bone metabolism. |
| P67 | [P67] A RANDOMIZED TRIAL OF CD4-GUIDED HAART INTERRUPTION IN PTS RECEIVING MOSTLY NNRTI-BASED REGIMENS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P67 M Olmo, D Podzamczer, L Ruiz, M Penaranda, F Gutierrez, J Niubo, J Romeu, M Larrousse, P Domingo, J Oteo, P Sanchez, I Ruiz, JL Aldeguer, J Iribarren Although minor HIV related conditions were observed, progression to AIDS or CD4 < 200 was not observed in TI pts. TI strategy allowed a therapy saving of 84%. Nadir and baseline CD4 influenced the need and timing of HAART reinitiation. |
| P68 | [P68] NO BENEFIT OF TREATMENT INTERRUPTIONS ON HIV-RELATED NEUROCOGNITIVE FUNCTIONING IN PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P68 Jose A Muñoz-Moreno, Carmina R Fumaz, Anna Prats, Maria J Ferrer, Eugènia Negredo, José Moltó, Raquel López-Blázquez, Maria T Garolera, Bonaventura Clotet TI may be a non-recommendable strategy for NF. Unexpected differences on NF exist when pts are assessed according to the existence of HAART interruptions. |
| P69 | [P69] ANTIRETROVIRAL TREATMENT AFTER CONTROLLED INTERRUPTIONS: A COMPARISION BETWEEN NON-NUCLEOSIDE AND PROTEASE INHIBITORS GROUPS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P69 Jose Perez-Silvestre, Francisco Garcia-Gonzalez, Roberto Oropesa, Victor Gonzalez-Valles, Vicente Abril, Miguel Garcia-Deltoro, Enrique Ortega We haven’t found significative differences between the rates of viral suppression at three months, although there is a tendency to greater suppression in NNRTI group. Six months and one year after there aren’t significative differences between NNRTI and PI groups. |
| P70 | [P70] ACUTE RETROVIRAL SYNDROME AFTER INTERRUPTION OF ANTIRETROVIRAL TREATMENT. DESCRIPTION OF 4 CASES Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P70 Ana Guelar, Luisa Sorli, Milagro Montero, Alicia González, Jordi Mercadal, Hernando Knobel Only a minority of patients developed acute retroviral syndrome after treatment interruption, but it can be life threatening. In most cases the patients presented a significant increase in viral load and a pronounced reduction of CD4 cell count. The predictive factors associated with this evolution are unknown. |
| P71 | [P71] STRUCTURED TREATMENT INTERRUPTIONS (STI) IN ACUTE HIV INFECTION IN TWO PATIENTS: A NEW APPROACH Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P71 Israel Yust, Nurith Vardinon, Irena Zeldis, Vered Hadas, Boaz Avidor, Dan Turner, Michael Burke The first patient demonstrates the possibility that multiple STI over a prolonged period may permit a decrease in duration of drug administration, without affecting immune or viral parameters. The second patient shows that stopping therapy after STI of brief duration did not prevent viral rebound and CD4 count fall shortly afterwards. There is no uniformity nor are there guidelines for STI. These preliminary results may encourage controlled STI studies to determine dose frequency vis a vis response. |
| Treatment Strategies - Other |
|
| P72 | [P72] DIFFERENT INFLUENCE OF ANTIRETROVIRAL DRUGS ON NEUROCOGNITIVE AND MOTOR FUNCTIONING IN HIV-INFECTED PATIENTS Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P72 Jose A Muñoz-Moreno, Carmina R Fumaz, Maria J Ferrer, Eugènia Negredo, Anna Prats, Maria T Garolera, Bonaventura Clotet In our study, NVP-based regimens were associated with a better NF compared with EFV- and LPV/rtv-based regimens. Antiretroviral therapy may produce a different impact on NF in HIV-infected people. |
| P73 | [P73] EFFICACY OF LOPINAVIR/RITONAVIR (LPV/R) IN CLINICAL PRACTICE: AN 18-MONTH OBSERVATIONAL PROSPECTIVE COHORT OF 1315 PATIENTS (KALEOBS COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P73 Jean-Michel Livrozet, Michel Dupon, Laurence Morand-Joubert, François-André Allaert, Alain Lafeuillade These results confirm the virological efficacy of LPV/r-containing regimens in ARV- or PI-naïve and PI-exp patients. Immune restoration was noted in all 3 populations. The benefit of LPV/r-based therapy was sustained, as demonstrated in patients followed up to M18. |
| P74 | [P74] THE EFFICACY OF NEVIRAPINE IN COMBINATION WITH TWO NUCLEOSIDE ANALOGUES IN THE TREATMENT OF HIV PATIENTS: 240 WEEK RETROSPECTIVE MULTICENTRE STUDY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P74 A Jayasuriya, J Arumainayagam, K Yoganathan, V Harindra, S Das, S Allan In this cohort, those who remained on Nevirapine maintained long-term viral suppression. A large proportion, however, discontinued nevirapine. Further work is needed to see if this drop-off rate lessens as clinicians become more confident in the recognition and management of nevirapine side-effects. |
| P75 | [P75] LONG-TERM SURVIVORS TREATED WITH DIFFERENT ANTIRETROVIRAL REGIMENS – RESIDUAL VIREMIA AND MODERATE LEVELS OF VIRAL LOAD Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P75 Loredana Manolescu, Paul Marinescu, Camelia Sultana, Simona Ruta In this study achieving higher levels of viral suppression did not confer greater CD4 cell count increases and higher levels of viral suppression did not predict reduced rates of virologic failure. Long-term studies are needed to determine whether the differences in immunological response seen here translate into differences in the risk of clinical disease taken into account the evolution of drug resistance and drug sequencing. |
| P76 | [P76] RITONAVIR BOOSTED SAQUINAVIR ONCE DAILY – AN INDIAN EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P76 Satish Kadappa, Bhimasena RS Rao, G V Mallesh, K N Praveenkumar Boosted PI regimens increase the potency and efficacy of the drug and lead to regimen simplification. Our cohort of patients who were on once daily ritonavir boosted saquinavir in a dose of 1600mg/100mg have experienced immunological benefits. The limitation of the present study is the small number of patients evaluated. For now, we cannot ignore the obvious benefits once daily ritonavir boosted saquinavir in HAART. |
| Adverse Effects - non-specific |
|
| P77 | [P77] TOLERABILITY OF BOOSTED PROTEASE INHIBITOR THERAPY IN CLINICAL PRACTICE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P77 David V Condoluci, Maryann Andrews, Paulette Dawn Slowinski, Marlene Folino, Kelly L Rand, Katherine Gallagher, William C Woodward In this retrospective analysis, BPI therapy was generally well tolerated with few significant adverse events or discontinuations for AEs. |
| P78 | [P78] TREATMENT WITH EFV+DDI+3TC IS AN EFFECTIVE, GENERALLY WELL TOLERATED AND WELL PERCEIVED COMBINATION IN INITIAL (I), SIMPLIFICATION (S) AND RESCUE (R) THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P78 H Knobel, J Hernandez-Quero, E Ribera, P Domingo, B Vendrell, O Serrano, J Perez-Molina H. del Mar, H. San Cecilio, H. Vall de Hebron, H. San Pau In the real-life conditions of this study, EFV+ddI+3TC was generally well tolerated and effective. G-3/4 liver toxicity was <2% and lipid parameters improved slightly. The most common AR were CNS-related not leading to Tx D/C in most cases. |
| P79 | [P79] EVALUATION OF THE LOCAL TOLERANCE AND QUALITY OF LIFE IN 60 HIV-1 INFECTED PATIENTS TREATED WITH AN ARV REGIMEN CONTAINING ENFUVIRTIDE: SURCOUF COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P79 Clotilde Allavena, Thierry Prazuck, Gwenael Le Moal, Thomas Jovelin, Fabienne Sauser, Veronique Reliquet, Francois Raffi During the study, more and more patients, especially self-injected ENF patients, get satisfied with ENF therapy. ISRs are frequent but mostly of minor or moderate intensity and do not prevent impovement in the QOL. |
| P80 | [P80] THE SAFETY AND THE EFFECTIVENESS OF ANTIRETROVIRAL THERAPY CONTAINING ATAZANAVIR/RITONAVIR (ATV/r) WITH OR WITHOUT TENOFOVIR (TDF) Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P80 Ana Guelar, Milagro Montero, Aitziber Ullaro, Luisa Sorli, Gabriel Vallecillo, Hernando Knobel Antiretroviral therapy containing Atazanavir/ritonavir with Tenofovir showed similar effectiveness and safety compared with regimens that did not contain this drug. However, a tendency of a greater incidence of hyperbilirubinemia was observed in the tenofovir group. |
| P81 | [P81] CAN NEVIRAPINE WARNING PREVENTS ADVERSE EVENTS IN ALL CLINICAL SETTINGS? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P81 Ana Guelar, Milagro Montero, Alexia Carmona, Sonia Luque, Nuria Berenguer, Alicia González, Hernando Knobel In our clinical setting, application of the warnings about the use of nevirapine could not prevent development of adverse events. Rashes were more frequent in patients without warning criteria. Hepatotoxicity was infrequent and developed later. |
| P82 | [P82] HLA-B*5701 CARRIAGE FREQUENCY IN A LONDON COHORT – WILL PROSPECTIVE SCREENING BE OF USE IN OUR POPULATION? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P82 Christopher Collister, Brett Marret, Simon Portsmouth, Alan Winston, Nicola E Mackie The demographics of the patients tested reflect our diverse clinic population. The prevalence of HLA-B*5701 in Black patients is higher than has been previously reported and interestingly is not significantly different than our Caucasian population. These findings are not in keeping with historic data reporting reduced rates of ABC HSR in patients of African origin assuming similar associations exist between carriage of HLA-B*5701 and ABC HSR in this group. |
| P83 | [P83] INCIDENCE OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P83 Suellen M Curkendall, James Richardson, Matthew F Emons Upon adjusting for other factors, ZDV use was associated with increased anemia risk in patients without baseline anemia and of worsening anemia in those with baseline anemia. Nearly 1/5 of new anemia cases among patients treated with ZDV required epo or blood transfusions. |
| P84 | [P84] DIRECT COSTS OF ANEMIA AMONG PATIENTS TREATED WITH ZIDOVUDINE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P84 S M Curkendall, Q V Doan, M F Emons, J Richardson, R J Halbert Patients treated with ZDV who experienced anemia required significantly more medical care and reported higher medical cost than patients without anemia. |
| P85 | [P85] CHANGES ON ERYTHROCYTE AND LYMPHOCYTE PROPERTIES PARTIALLY REVERSED IN PATIENTS UNDERGOING ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P85 Nuno C Santos, J Martins-Silva, M Doroana, N Duarte, L Tavares, F Antunes, Carlota Saldanha Our data shows that the HIV-1 infection of a patient leads to biophysical changes on the membrane of lymphocytes (mostly non-infected) and erythrocytes, partially reversed by HAART. The observations are consistent with a process of facilitated propagation of the infection to new cells, stimulation of virion production and maintenance of a reservoir of erythrocyte-bound infectious virus. |
| P86 | [P86] DOES ANTIRETROVIRAL DRUG THERAPY ALTER THE CLINICAL OUTCOME IN HIV POSITIVE PATIENTS AFTER ORAL AND MAXILLOFACIAL SURGERY? Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P86 Kishore Shetty HIV seropositive status was found to be an independent risk factor for complications of major oral surgical procedures. The most important risk factors for complication of surgery in HIV positive individuals were high viral load and absence of higly active antiretroviral treatment. |
| Adverse Effects - Bone |
|
| P87 | [P87] RISK FACTORS OF OSTEOPOROSIS IN HIV-INFECTED WOMEN: NO ROLE OF ANTIRETROVIRAL THERAPY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P87 A Libois, S Rozenberg, K Kabeya, M Gerard, B Poll, E Goudeseune, M Tondeur, N Clumeck In this population of HIV-infected women, mainly composed of African women, there was no association between antiretroviral therapy (containing PI or not) and BMD loss. |
| P88 | [P88] PREVALENCE AND RISK FACTORS FOR OSTEOPENIA/OSTEOPOROSIS IN SLOVENIAN HIV INFECTED MALE POPULATION; A NATIONAL SURVEY Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P88 Janez Tomazic, Katja Ul, Gabriele Volcanek, Samo Gorenek, Mia Pfeifer, Ludvik Vidmar, Primoz Karner According to published data, the highest proportion of the national HIV-infected population was included. The prevalence of reduced BMD was significantly higher than the national prevalence among males. There was no association between reduced BMD and any specific ART. According to our results, reduced BMD was related to HIV itself. None of the multiple established risk factors turned out to predict reduced BMD. Screening and treatment of reduced BMD present a reasonable strategy for preventing reduced BMD in HIV-infected patients, but adjusting vitamin D could be an important component, as well. |
| Adverse Effects - Cardiovascular |
|
| P89 | [P89] CEREBRO- AND CARDIOVASCULAR EVENTS AND CARDIOVASCULAR MORTALITY IN HIV-INFECTED PATIENTS WERE SIGNIFICANTLY INCREASED AFTER THE INTRODUCTION OF HAART Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P89 Paula Freitas, Davide Carvalho, Tiago Costa, Margarida Tavares, Joana Rema, Rui Marques, Fernando Lopes, António Mota-Miranda, José Luis Cerebro and cardiovascular events, as well as cardiovascular mortality, increased significantly after 1997, when HAART became available. |
| P90 | [P90] CARDIOVASCULAR RISK FACTORS IN HIV INFECTED WOMEN FROM THE SPANISH VACH COHORT Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P90 Maria Jose Galindo, Paloma Geijo, Maria Luisa Garcia-Alcalde, Ignacio Suarez-Lozano, Pere Domingo The HIV infected women on treatment are at higher risk of developing a coronary event than the Spanish population. This risk is lower than the HIV infected men of the VACH cohort. |
| P91 | [P91] USE OF FRAMINGHAM RISK SCORE AND DIAGNOSIS OF METABOLIC SYNDROME TO IDENTIFY HIV PATIENTS WITH A HIGH CARDIOVASCULAR RISK PROFILE IN CLINICAL PRACTICE: AN ITALIAN MULTICENTRIC EXPERIENCE Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. P91 Giuseppe VL De Socio, Giordano Madeddu, Marzia Franzetti, Elena Rosella, Francesca Vichi, Carmela Grosso, Sara Melzi, Patrizia Marconi, Giustino Parruti, Paolo Bonfanti The combined use of the diagnostic criteria for Metabolic Syndrome and the Framingham-Risk Score may represent a simple clinical tool for identifying high-risk HIV infected patients, worth further diagnostic interventions. |
| P92 | [P92] PATIENTS’ AWARENESS OF ANTIRETROVIRAL-RELATED CARDIOVASCULAR RISK AND THEIR PREFERENCES ON HOW TO MANAGE IT Int Cong Drug Therapy HIV 2006 |